Buy Truqap in India — Price & Availability

What is Truqap used for?

Truqap (capivasertib) is an oral AKT inhibitor. It blocks the kinase activity of all three isoforms of AKT (AKT1, AKT2, and AKT3) — a key node in the PI3K/AKT signalling pathway that cancer cells rely on for growth, survival, and division. By interrupting this pathway, Truqap helps slow the growth of tumours driven by these signals.

It is approved, in combination with fulvestrant, for adults with:

• HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations, following progression on at least one endocrine-based regimen in the metastatic setting, or recurrence on or within 12 months of completing adjuvant therapy.

It is also approved, in combination with abiraterone and prednisone, for adults with:

• PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer

The presence of a PIK3CA, AKT1, or PTEN alteration must be confirmed by an approved test before treatment begins. It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.

Recommended dosage:

The recommended dose of Truqap is 400 mg (two tablets) taken orally twice daily (about 12 hours apart), with or without food, on an intermittent schedule of 4 days on followed by 3 days off, each week. Treatment continues until disease progression or unacceptable toxicity. Truqap is given together with fulvestrant, which is administered separately per its own prescribing information.

• Tablets are swallowed whole — do not chew, crush, or split them, and do not take tablets that are broken, cracked, or not intact.
• If a dose is missed by more than 4 hours, or if the patient vomits after a dose, they should skip that dose and take the next dose at its usual scheduled time.
• Fasting blood glucose (FG) and HbA1c are checked before starting Truqap and at regular intervals during treatment.
  If side effects occur, the dose may be reduced in steps as directed by the treating doctor.

The treating oncologist always determines the exact dose and any modifications.

Boxed Warnings: Truqap can cause high blood glucose, which in some cases has been severe, including diabetic ketoacidosis. Blood glucose and HbA1c are monitored before and during treatment; patients with diabetes or risk factors need close monitoring, and treatment may be adjusted or paused to manage this.

• Diarrhoea: Very common and can be severe, leading to dehydration; report loose or watery stools early so it can be managed with fluids or medicines.
• Skin (cutaneous) reactions: Common and sometimes severe, including rash, redness, dryness, blistering, or peeling; report new or worsening skin symptoms promptly, as most appear within the first two weeks.
• Drug interactions: Truqap interacts with CYP3A inhibitors and inducers — the dose may need reducing with moderate CYP3A inhibitors, and strong or moderate CYP3A inducers should generally be avoided. It also affects certain transporters and CYP2D6 substrates, so share a full medication list with the treating team.
• Contraindication: Truqap should not be used in patients with severe hypersensitivity to capivasertib or any of its components.
• Pregnancy and breastfeeding: Capivasertib may harm an unborn baby; effective contraception is advised during and for a period (about 4 months) after the last dose, and breastfeeding is not recommended during and for a period after treatment.

Common side effects:
Frequently reported effects include diarrhoea, skin reactions/rash, increased blood glucose, nausea, tiredness (fatigue), vomiting, mouth sores (stomatitis), decreased appetite, headache, and changes in certain blood tests (such as low potassium, low haemoglobin/anaemia, and altered blood counts). This is not a complete list — refer to the full prescribing information and your oncologist.

Patients in India can legally access Truqap through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
  Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Import & delivery — Truqap is sourced and shipped under validated, temperature-controlled conditions to the patient or treating hospital.

Documents required to import Truqap:

• A valid prescription from a qualified oncologist
• The patient’s diagnostic reports, including PIK3CA/AKT1/PTEN alteration test results
• Government-issued patient ID proof
• An import permit, where applicable

Because Truqap is not sold on the open market in India, there is no fixed MRP. The Truqap cost in India depends on a few factors at the time of import:

• The number of tablets and the pack size required per cycle, which is based on the prescribed dose (the standard dose is 400 mg twice daily on a 4-days-on, 3-days-off schedule).
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Logistics, insurance, and any applicable customs duties or import permit costs.
• Get a transparent quote: We provide a written quotation covering Truqap cost, logistics, and delivery timeline once a valid prescription is shared. Request your Truqap quote →

Truqap is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid oncologist’s prescription, in line with applicable regulations.

Indian Pharma Network sources Truqap from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. Truqap tablets are stored at room temperature, 20 °C to 25 °C (68 °F to 77 °F), in the original packaging. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Truqap can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status:
Truqap first received US FDA approval on 16 November 2023 for use with fulvestrant to treat HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, after progression on endocrine-based therapy. Alongside the approval, the FDA cleared the FoundationOne CDx assay as a companion diagnostic to identify eligible patients. Truqap has also been authorised in the European Union and other markets for this breast cancer indication. As of the current publicly available information, Truqap in India is not commercially marketed, which is why the Named Patient route is used.